通过使用CRISPR/Cas9技术,生成一种抗CD5CAR人类诱导的多能干细胞系
Shuoting Wang1, Xinrui Guo2, Han Yan2
1Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, PR China.
Stem cell research
|May 10, 2025
概括
研究人员使用CRISPR/Cas9.9设计了一种新的抗CD5仿真抗原受体 (CAR) T细胞疗法. 这种创新方法有效地准了CD5相关的血液癌症,如淋巴瘤和白血病.
科学领域:
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
- 血液学 血液学 血液学
背景情况:
- 化学抗原受体 (CAR) T细胞疗法是治疗血液性恶性瘤的一个有前途的方法.
- CD5是一种细胞表面抗原,在恶性T细胞上表达,使其成为可行的治疗点.
- 现有的CAR T细胞疗法在向特定的血液癌症方面面临挑战.
研究的目的:
- 开发一种新的抗CD5CAR T细胞疗法,用于治疗CD5相关的血液性恶性瘤.
- 设计一种表达抗CD5 CAR结构的稳定的人类诱导多能干细胞 (iPSC) 线.
- 为了验证工程 iPSC 线的功能和安全性.
主要方法:
- 使用CRISPR/Cas9基因编辑技术进行精确的基因改造.
- 产生了一条稳定表达抗CD5 CAR 结构的敲进iPSC线.
- 用于CAR表达式检测和验证的FLAG标签和GFP标记.
主要成果:
- 成功生成了一个稳定的抗CD5CAR敲进iPSC线.
- 通过FLAG标签和GFP检测到的确认稳定的CAR构造表达.
- 证明了干细胞形态的维持,正常的型和多能性标志物.
- 确认了工程 iPSC 系列的保留差异化潜力.
结论:
- 设计的抗CD5 CAR iPSC系列代表了开发向T细胞治疗的可行平台.
- 这种方法显示出治疗CD5相关的血液性恶性瘤 (如T细胞淋巴瘤和白血病) 的潜力.
- 具有特征的iPSC系列为进一步临床前和临床开发CAR T细胞疗法提供了基础.
相关概念视频
01:59CRISPR
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...
01:28CRISPR/Cas9 Genome Editing
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...